Dr Geoffrey Guy, GW's Chairman, said, "This agreement represents a landmark
event in the history of GW. Not only have we secured the development and
marketing of our lead product, Sativex, in the world's largest market, we have
also selected a strategic partner that will allow us to extend our cannabinoid
pipeline. Otsuka has an excellent US commercial track record and a world leading
CNS science base. We are delighted to be working with Otsuka to fulfill our
ambition of developing a range of novel cannabinoid medicines to meet serious
unmet medical needs."

micky..i think people were stocking up today...tomoros press should give it a boost